The ONE STOCK to Watch as Trump’s Billionaire Team Takes Over Washington (Not Truth Social)

Donald Trump has officially assembled the wealthiest administration in American history… and it’s not even close. With a combined net worth of $340 billion, this cabinet is obscenely rich. We’re talking about “buy a private island for fun” levels of wealth. And that number could still climb higher if a few more billionaires decide to RSVP.

Leading the pack is biotech bro and FDA nemesis Vivek Ramaswamy. With $670 million in Roivant Sciences stock and an ego to match, Vivek is all set to mold the FDA into his personal piggy bank.

(Source: The Business Journal)

Ramaswamy has spent years bashing the FDA, calling it the “Failed Drug Administration” and suggesting we’d all be better off if drug approvals worked like Yelp reviews. Now, thanks to Trump’s “Department of Government Efficiency” (DOGE), Vivek has the clout to turn those rants into policy. His big idea is to cut the FDA’s two-trial approval standard down to one. Sounds efficient, right? Sure… if you’re a biotech CEO looking to rush your drugs to market before anyone notices they might have side effects.

And guess who benefits the most from this regulatory shortcut? Ding, ding, ding… Roivant Sciences. Vivek’s former company has a pipeline of experimental drugs just waiting for the FDA’s green light. With trial results expected in 2025, a fast-track approval process could turn that $670 million stake into, well, a lot more. Critics are calling this a conflict of interest. Vivek? He’s calling it a win-win. “Reducing the cost of drug development helps everyone!” he insists, conveniently ignoring the fact that "everyone" includes himself.

Not everyone’s drinking the Ramaswamy Kool-Aid. FDA Commissioner Robert Califf pulled no punches, reminding us of thalidomide, the 1960s wonder drug that turned into a public health nightmare and caused deformities in children. Califf’s point? The FDA exists to stop stuff like that from happening again. But Vivek doesn’t seem too worried about patient safety. Instead, he’s all about dismantling what he calls the FDA’s “micromanagement” to level the playing field for “smaller biotechs.” Seems to me like he might be saying “Big Pharma already has billions, so let’s help the little guys (like, say, Roivant) catch up.”

Of course, Vivek isn’t the only deep-pocketed player in Trump’s cabinet. Elon Musk, Linda McMahon, and a handful of hedge fund moguls round out the roster, making Trump’s 2016 lineup look like the JV team. Together, they’re rewriting “drain the swamp” to mean “drain regulations that get in our way.”

All jokes aside... with Ramaswamy’s FDA playbook, the line between public policy and private profit is blurrier than ever. But one thing is certain: if you’re looking for a high stakes play that could potentially go batsh*t crazy over the next few years… you should look into buying Roivant, because I’m willing to bet that it’s going to benefit from some policies in the near future.

PS: Big news… we’ve officially leveled up! We’re now the “Official Trading Alert Service of People Who Hate Missing Big Gains.” (OK, we gave ourselves that title, but hey, 115,000 members can’t all be wrong, right?)

To keep things interesting, we’re ditching the boring routine. Our next trade alerts? They’ll drop randomly, keeping you on your toes. Want to be the first to pounce on these opportunities? Then you’ll need to join Stocks.News Premium.

Here’s the deal: Premium gives you real-time alerts and access to our Insider Trading tool. Yep, the same one that lets you peek into what Capitol Hill’s finest (looking at you, Nancy) are doing with their "public servant" millions. Plus, you’ll get cutting-edge indicators and multiple trade alerts every week… all for less than what you'd pay for HBO Max (and way less depressing than watching another "Succession" re-run).

No strings, no long-term commitments. Just actionable intel that could seriously change your trading game. Click here and see what you’ve been missing.

Stock.News does not have positions in companies mentioned.